Antiviral susceptibilities of herpes simplex virus isolates from infants with recurrent mucocutaneous lesions after neonatal infection.
Antiviral susceptibilities of herpes simplex virus isolates from infants with recurrent mucocutaneous lesions after neonatal infection.
复制标题
新生儿感染后皮肤粘膜病变复发的婴儿分离的单纯疱疹病毒的抗病毒敏感性。
DOI：
--
复制
发表时间：
1989
期刊：
影响因子：
--
通讯作者：
M. Levin
中科院分区：
文献类型：
--
作者：
G. Rabalais;S. Nusinoff;A. Arvin;M. Levin
许多婴儿在完成新生儿单纯疱疹病毒（HSV）感染的抗病毒治疗后发生复发性粘膜病变。为了确定这些复发是否由对阿昔洛韦或阿糖腺苷产生耐药性的病毒引起，我们测试了22个治疗前和32个治疗后分离的22个3个月以下婴儿的HSV病毒的抗病毒药物敏感性。16例用阿昔洛韦治疗，6例用阿糖腺苷治疗。通过酶联免疫吸附试验测量抗病毒敏感性，并以50%抑制剂量表示。所有HSV分离株对阿昔洛韦的50%抑制剂量均小于1.0微克/毫升。治疗前分离株的平均阿糖腺苷50%抑制剂量为11.4微克/ml，治疗后分离株为8.9微克/ml。对于对阿昔洛韦或阿糖腺苷耐药的HSV复发，不选择抗病毒治疗。
Recurrent mucocutaneous lesions occur in many infants after completion of antiviral therapy of neonatal herpes simplex virus (HSV) infection. To determine whether these recurrences were caused by viruses that had become resistant to acyclovir or vidarabine, we tested the antiviral susceptibilities of 22 pretherapy and 32 posttherapy HSV isolates from 22 infants younger than 3 months of age. Sixteen had been treated with acyclovir and six with vidarabine. Antiviral susceptibilities were measured by an enzyme-linked immunosorbent assay and are expressed as the 50% inhibitory dose. All HSV isolates had a 50% inhibitory dose for acyclovir of less than 1.0 micrograms/ml. The mean vidarabine 50% inhibitory dose was 11.4 micrograms/ml for pretherapy isolates and 8.9 micrograms/ml for posttherapy isolates. Antiviral therapy did not select for recurrences with HSV resistant to acyclovir or vidarabine.